Allogeneic stem cell transplantation for high-risk leukaemias
Prevention and treatment of relapse following allogeneic stem cell transplantation
Immune escape mechanisms in myeloid diseases
Clinical projects:
Integration of targeted radionuclide therapy into conditioning
Optimised drug and cellular therapy for AML relapse following allo-SCT
Optimised nutrition during allo-SZT
Registry studies: including
Allogeneic second-line transplantation in AML and MDS
Use of prophylactic transfusion of donor lymphocytes
GvHD prophylaxis with reduced ptCy
Experimental studies:
Spatial transcriptomics for the detection of immune escape mechanisms in relapsed leukaemic diseases
Immune escape in extramedullary leukaemic diseases
Effect of checkpoint inhibitors on the allogeneic immune response
Velázquez GF, Weller JF, Rubeck A, Arndt T, Schiele S, Mezger M, Lengerke C, Bethge W, Trepel M, Müller G, Christopeit M, Schmid C. Prophylactic and pre-emptive donor lymphocyte infusion in patients with acute myeloid leukaemia and myelodysplastic syndrome – Validation of current recommendations and proposal of a modified outcome assessment. Haematologica. 24 April 2025. doi: 10.3324/haematol.2024.287206
Giuliano Filippini Velázquez,Philipp Anand, Joudi Abdulmajid, Xiaojia Feng, Jan Frederic Weller, Klaus Hirschbuehl, Helga Schmetzer; Christoph Schmid* Clinical Stabilisation of a Highly Refractory Acute Myeloid Leukaemia Under Individualised Treatment with Immune Response Modifying Drugs by In Vivo Generation of Dendritic Cells of Leukaemic Origin (DCleu) and Modulation of Effector Cells and Immune Escape Mechanisms Biomarker Research 15 August 2025;13(1):104.doi: 10.1186/s40364-025-00817-8
Schmälter AK, Labopin M, Versluis J, Gallego Hernanz MP, Eder M, von dem Borne P, Socié G, Chevallier P, Forcade E, Neubauer A, Baron F, Bazarbachi A, Bug G, Nagler A, Schmid C*, Esteve J, Mohty M, Ciceri F. The role of allogeneic stem cell transplantation in acute myeloid leukaemia with translocation t(8;16)(p11;p13) Am J Hematol. 2025 Jan;100(1):85-92. doi: 10.1002/ajh.27496.
Ann-Kristin Schmaelter, Maud Ngoya, Jacques-Emmanuel Galimard, Ali Bazarbachi, Jürgen Finke, Nicolaus Kröger, Martin Bornhauser, Matthias Stelljes, Friedrich Stölzel, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor-Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Arnon Nagler, Christoph Schmid* Fabio Ciceri, and Mohamad Mohty Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukaemia – an EBMT registry analysis of 1540 patients. Blood Cancer J. 2 May 2024;14(1):76. doi: 10.1038/s41408-024-01060-4
Simona Pagliuca MD, Christoph Schmid MD (contr. equally), Nicole Santoro MD, Federico Simonetta MD, Giorgiia Battipaglia MD, Prof. Thierry Guillaume MD, Raffaella Greco MD, Prof. Francesco Onida MD, Isabel Sánchez-Ortega MD, Prof. Ibrahim Yakoub Agha MD, Prof. Jurgen Kuball MD, Prof. Mette D. Hazenberg MD, Annalisa Ruggeri MD Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the Practice Harmonization and Guidelines Committee and the Cellular Therapy and Immunobiology Working Party of the EBMT. Lancet Haematol. 2024 Jun;11(6):e448-e458. doi: 10.1016/S2352-3026(24)00098-X PMID: 38796194
